An LRRK2 kinase inhibitor or an ARP2/3 inhibitor prevents microglial activation and neurotoxicity in vitro169,170, suggesting the involvement of the LRRK2-WAVE2 pathway in microglia in PD pathogenesis. Here, WASF2 is linked to Parkinson disease.